Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Modern Diagnostic & Research Centre Buyback Yield %?
Modern Diagnostic & Research CentreBOM:544673 15 Buyback Yield % is -42.23 as of Aug. 27, 2026. GuruFocus rates BOM:544673 with a GF Score™ of 15/100. The stock has 7 warning signs investors should review. Among 81 Medical Diagnostics & Research companies, Modern Diagnostic & Research Centre ranks worse than 87.65% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Diagnostic & Research Centre Buyback Yield % Chart
Modern Diagnostic & Research Centre Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Buyback Yield %
0.00
0.00
0.00
-40.17
Modern Diagnostic & Research Centre Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Buyback Yield %
0.00
0.00
0.00
-40.17
BOM:544673 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Modern Diagnostic & Research Centre's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Diagnostic & Research Centre Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Modern Diagnostic & Research Centre's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Modern Diagnostic & Research Centre's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Diagnostic & Research Centre (BOM:544673) has a Buyback Yield % of -42.23 as of Aug. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Modern Diagnostic & Research Centre and its competitors. According to the industry distribution chart, Modern Diagnostic & Research Centre ranks #71 out of 81 companies in the Medical Diagnostics & Research industry, placing it in the top 87.7%.
Is Modern Diagnostic & Research Centre's Buyback Yield % too high?
Modern Diagnostic & Research Centre's current Buyback Yield % is -42.23. Based on the distribution chart, Modern Diagnostic & Research Centre ranks #71 out of 81 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Modern Diagnostic & Research Centre has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Modern Diagnostic & Research Centre's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Modern Diagnostic & Research Centre ranks #71 out of 81 companies for Buyback Yield %. This places Modern Diagnostic & Research Centre in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Modern Diagnostic & Research Centre and its competitors. Modern Diagnostic & Research Centre's current Buyback Yield % is -42.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Diagnostic & Research Centre stock overvalued right now?
Modern Diagnostic & Research Centre (BOM:544673) has a current Buyback Yield % of -42.23. The current Buyback Yield % is -42.23. Modern Diagnostic & Research Centre's overall GF Score™ is 15/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Modern Diagnostic & Research Centre (BOM:544673), the current Buyback Yield % is -42.23 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modern Diagnostic & Research Centre Ltd is a services provider in diagnostic and related healthcare tests services in India. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through Its integrated, nationwide network, it offers a complete range of diagnostic facilities in radiology and pathology. The company provides healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
15GF Score
Get the complete analysis for BOM:544673
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544673 has been successfully added to your 
